Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

TZP-101

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Ulimorelin Hyrdrochlorideulimorelin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Pathophysiology and pharmacotherapy of gastroparesis: current and future perspectives
Introduction: Gastroparesis is an important clinical disorder characterised by delayed gastric emptying in the absence of… 
Highly Cited
2011
Highly Cited
2011
Randomised clinical trial: ghrelin agonist TZP‐101 relieves gastroparesis associated with severe nausea and vomiting – randomised clinical study subset data
Aliment Pharmacol Ther 2011; 33: 679–688 
Highly Cited
2011
Highly Cited
2011
Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic.
High-throughput screening of Tranzyme Pharma's proprietary macrocycle library using the aequorin Ca2+-bioluminescence assay… 
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Highly Cited
2010
Highly Cited
2010
Safety and efficacy of ghrelin agonist TZP‐101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo‐controlled study
Background  Gastroparesis, a chronic disorder of abnormal gastric motility, is common in patients with diabetes mellitus. A… 
Highly Cited
2010
Highly Cited
2010
The Ghrelin Agonist TZP-101 for Management of Postoperative Ileus After Partial Colectomy: A Randomized, Dose-Ranging, Placebo-Controlled Clinical Trial
PURPOSE: Ghrelin agonist TZP-101 is a potent prokinetic. This phase 2b study evaluated TZP-101 safety and efficacy in… 
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2009
Highly Cited
2009
Ghrelin receptor agonist (TZP‐101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis
Background  TZP‐101 is a synthetic, selective ghrelin agonist in development for gastroparesis. 
2009
2009
Effect of the ghrelin receptor agonist TZP-101 on colonic transit in a rat model of postoperative ileus.
Ghrelin, the natural ligand of the growth hormone secretagogue receptor (ghrelin receptor), is an orexigenic gut hormone with… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2008
Highly Cited
2008
Ghrelin Agonist (TZP‐101): Safety, Pharmacokinetics and Pharmacodynamic Evaluation in Healthy Volunteers: A Phase I, First‐in‐Human Study
The authors evaluate the human safety, tolerability, pharmacokinetics, and pharmacodynamics of TZP‐101, an agonist of the hGHS… 
2008
2008
Pharmacological demarcation of the growth hormone, gut motility and feeding effects of ghrelin using a novel ghrelin receptor agonist.
The peptide hormone ghrelin exerts a wide spectrum of activities including the stimulation of GH release, feeding, and… 
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2007
Highly Cited
2007
Prokinetic Effects of a New Ghrelin Receptor Agonist TZP-101 in a Rat Model of Postoperative Ileus
Postoperative ileus (POI) is a major cause of postoperative complications and prolonged hospitalization. Ghrelin, which is the… 
  • table 1
  • figure 2
  • figure 1
  • table 2
  • figure 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE